Study of Latinos (SOL) Ojos

项目概要/摘要 本申请为西班牙裔社区健康研究/拉丁裔研究提出了一项辅助眼科研究 (HCHS/SOL）。HCHS/SOL是一项前瞻性的、基于人群的、多中心队列研究，由国家心脏基金会资助， 肺和血液研究所（NHLBI）和其他6个国立卫生研究院（NIH）研究所，旨在 1)评估疾病负担; 2）解决心血管疾病（CVD）、中风、哮喘、慢性阻塞性肺疾病（COPD） 肺病、睡眠障碍、龋齿和牙周病、听力障碍、糖尿病， 肾脏和肝脏疾病以及认知障碍。这项具有里程碑意义的研究，是有史以来规模最大的一次， 西班牙裔/拉丁美洲人，构成了广泛的，高质量的表型和基因型数据的国家资源。 与会者包括墨西哥人、古巴人、多米尼加人、波多黎各人、中美洲和南美洲人， 其他起源。HSHC/SOL招募了16，415名参与者进行访视#1（2008-2011）;访视#2的数据收集 （2014-2017）完成12/17（芝加哥和迈阿密现场中心：82.3%的参与率）;以及，NHLBI 合同HCHS/SOL访问#3（2019-2022）资金作为辅助研究的平台。我们将招募 对来自芝加哥和迈阿密的2500名年龄≥40岁的HCHS/SOL参与者进行详细的眼科检查， 与访视#3一致。HCHS/SOL协调中心将为老年人的过度抽样提供指导 最大限度地提高疾病检测效率，抽样权重反映选择的概率，以保持 准确的流行率。在HCHS/SOL不同背景的拉丁美洲人代表了丰富的社会文化， 基因混合组，继承了欧洲，美洲土著和非洲血统的混合物， 以前被隔离的人群。因此，HCHS/SOL眼科研究将代表第一只高度混合的眼睛。 流行病学队列这种异质性和内在变异性在基础和临床研究中至关重要， 创新性地将HCHS/SOL眼科研究定位为在普遍风险中评估重要的病因途径 无法用同质队列评估的因素和结果。我们建议收集高质量的 眼睛结果数据，与国家眼科研究所（NEI）资助的基于人群的队列相同，这将允许 眼流行病学界，第一次，评估新的假设与系统性 疾病在一个良好的特征，多样化的队列。HCHS/SOL眼科研究旨在1）评估和 比较2010年西班牙裔/拉丁裔群体慢性眼病的年龄标准化患病率 使用先前构建的HCHS/SOL“遗传分析组”（大陆：墨西哥人、中部和 南美洲人;和，加勒比：古巴人，多米尼加人，和波多黎各人）;和，2）评估是否 流行性疾病与新的CVD、生物医学和社会文化风险因素相关。提出 这项研究利用了NHLBI资助的流行病学研究，该研究得到了其他6个NIH研究所的支持， 这是高度创新和高效的流行病学眼科研究的重要机会。

PROJECT SUMMARY/ABSTRACT This application proposes an ancillary eye study to the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). HCHS/SOL is a prospective, population-based, multicenter cohort, funded by the National Heart, Lung, and Blood Institute (NHLBI) and 6 other National Institutes of Health (NIH) Institutes, that is designed to 1) assess disease burden; and, 2) address cardiovascular disease (CVD), stroke, asthma, chronic obstructive pulmonary disease, sleep disorders, dental caries and periodontal disease, hearing impairment, diabetes, kidney and liver disease, and cognitive impairment. This landmark study, the largest ever conducted in Hispanics/Latinos, constitutes a national resource of extensive, high-quality phenotypic and genotypic data. Participants include those of Mexican, Cuban, Dominican, Puerto Rican, Central and South American, and Other origins. HSHC/SOL recruited 16,415 participants for Visit #1 (2008-2011); data collection for Visit #2 (2014-2017) concluded 12/17 (Chicago and Miami Field Centers: 82.3% participation rate); and, NHLBI contracted HCHS/SOL Visit #3 (2019-2022) funding to serve as a platform for ancillary studies. We will recruit and perfom a detailed eye exam on 2500 HCHS/SOL participants from Chicago and Miami aged ≥40 years to coincide with Visit #3. The HCHS/SOL Coordinating Center will provide direction in oversampling older adults to maximize disease detection efficiency, with sampling weights reflecting probabilities of selection to maintain accurate prevalence rates. Latinos of diverse backgrounds as in HCHS/SOL represent a rich sociocultural and genetically admixed group, inheriting a mixture of European, Native American, and African ancestry from populations previously isolated. As such, the HCHS/SOL Eye Study will represent the first highly admixed eye epidemiology cohort. This heterogeneity and intrinsic variability, essential in basic and clinical research, innovatively positions the HCHS/SOL Eye Study to assess important etiologic pathways amid prevalent risk factors and outcomes that cannot be assessed with homogenous cohorts. We propose to collect high-quality eye outcome data, identical to National Eye Institute (NEI)-funded population-based cohorts, which will allow the eye epidemiology community to, for the first time, assess novel hypotheses associated with systemic disease in a well-characterized, diverse cohort. The HCHS/SOL Eye Study is designed to 1) assess and compare the 2010 age-standardized prevalence of chronic eye disease across Hispanic/Latino groups using previously constructed HCHS/SOL “genetic analysis groups” (Mainland: Mexicans, Central and South Americans; and, Caribbean: Cubans, Dominicans, and Puerto Ricans); and, 2) assess whether prevalent disease is associated with novel CVD, biomedical, and sociocultural risk factors. Proposed research leverages NHLBI-funded epidemiologic research supported by 6 other NIH Institutes, and represents a significant opportunity for highly innovative and efficient epidemiologic eye research.